Select Page
New Cancer Drugs Approved in 2023

New Cancer Drugs Approved in 2023

New Cancer Drugs Approved in 2023 In 2023, the U.S. Food and Drug Administration (FDA) approved several new cancer drugs that offer promising treatment options for patients. Here are some of the key cancer drug approvals from the past year: Pembrolizumab Plus...
FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma The FDA has approved belzutifan (Welireg) for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior therapy with a PD-1/PD-L1 inhibitor and a VEGF-TKI[1][2][4][5]....
FDA Approves Mirvetuximab Soravtansine-gynx for Ovarian Cancer

FDA Approves Mirvetuximab Soravtansine-gynx for Ovarian Cancer

FDA Approves Mirvetuximab Soravtansine-gynx for Ovarian Cancer On March 22, 2024, the FDA approved mirvetuximab soravtansine-gynx (Elahere) for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who...